{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:43Z","timestamp":1791661903447,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000196","name":"Fondation canadienne pour l'innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.orcp.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:14:42Z","timestamp":1791321282000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015\u20132023"],"prefix":"10.1016","author":[{"given":"Payam","family":"Peymani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Aboulatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0966-5475","authenticated-orcid":false,"given":"Mohd Wasif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-3590","authenticated-orcid":false,"given":"Roxana","family":"Dragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-5406","authenticated-orcid":false,"given":"Sherif","family":"Eltonsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.orcp.2026.10.001_bib1","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.2337\/dc26-S015","article-title":"American Diabetes Association Professional Practice Committee for Diabetes. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2026.10.001_bib2","first-page":"2401","article-title":"Global trends in prevalence of maternal overweight and obesity: a systematic review and meta-analysis of routinely collected data retrospective cohorts","volume":"9","author":"Kent","year":"2024","journal-title":"Int J Popul Data Sci"},{"key":"10.1016\/j.orcp.2026.10.001_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"issue":"537","key":"10.1016\/j.orcp.2026.10.001_bib4","first-page":"1","article-title":"GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024","author":"Vahratian","year":"2025","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.orcp.2026.10.001_bib5","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/dc20-2926","article-title":"Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA","volume":"44","author":"Shin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2026.10.001_bib6","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. JARDIANCE (empagliflozin tablets), for oral use: Prescribing information. 2025 Oct. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204629s063lbl.pdf."},{"key":"10.1016\/j.orcp.2026.10.001_bib7","unstructured":"Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use: Prescribing information. 2025. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"10.1016\/j.orcp.2026.10.001_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.orcp.2026.10.001_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.orcp.2026.10.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.orcp.2026.10.001_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/AOG.0000000000006161","article-title":"Prescribing trends in glucagon-like peptide-1 medications among pregnant and postpartum persons","volume":"147","author":"Lessard","year":"2026","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.orcp.2026.10.001_bib12","unstructured":"Paterson J.M., Wu F, Yu O, Hamad A., Dahl M., Janzen D., et al. Utilization of Antidiabetic Drugs During Pregnancy. 2025. Available: https:\/\/www.cda-amc.ca\/sites\/default\/files\/hta-he\/HC0083-Report.pdf."}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X2600092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X2600092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:35:31Z","timestamp":1791660931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X2600092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"alternative-id":["S1871403X2600092X"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2026.10.001","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015\u20132023","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}